Article (Scientific journals)
A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss
Reginster, Jean-Yves; Deroisy, Rita; Lecart, M. P. et al.
1995In American Journal of Medicine, 98 (5), p. 452-8
Peer Reviewed verified by ORBi
 

Files


Full Text
A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss.pdf
Publisher postprint (975.47 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] PURPOSE: Nasal administration of salmon calcitonin (SCT) has been suggested for preventing trabecular bone loss during the first years following the menopause, but no conclusive evidence has appeared about the minimal effective dose. Since nasal calcitonin is highly expensive, it makes sense to define this dose. PATIENTS AND METHODS: We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design. The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism. They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83). All treatments were given on 5 consecutive days per week. Statistical analysis was based on two populations: intention-to-treat (IT) and valid completers (VC). The main assessments performed were bone mineral density of the lumbar spine (LSBMD) and biochemical parameters reflecting bone turnover (serum alkaline phosphatase, urinary calcium/creatinine, and hydroxyproline/creatinine ratios). RESULTS: Changes over the treatment period were comparable in the IT and VC populations. In the group receiving the placebo, LSBMD decreased from baseline to end point by a mean of 6.28% (95% confidence interval [CI] -7.69 to -4.89) in the IT population and 6.98% (95% CI -8.86 to -5.11) in the VC population (P = 0.0001, end LSBMD versus baseline LSBMD). LSBMD increased slightly with the 50-IU/d dose of SCT, by 0.82% (95% CI -0.26 to 1.89) in the IT population, and 0.51% (95% CI -0.69 to 1.72) in the VC (P = NS, versus baseline). Subjects who received SCT 200 IU/d experienced significant increases of 2.03% (95% CI 0.92 to 3.15) in the IT population and 2.26% (95% CI 1.01 to 3.51) in the VC (both P = 0.001). The difference between the evolution of the combined groups receiving nasal SCT and the group treated with the placebo was highly significant (P = 0.0001). No significant changes were recorded in biochemical parameters reflecting bone turnover. CONCLUSIONS: SCT 50 IU/d administered nasally and intermittently appears to prevent lumbar bone loss in nonobese early postmenopausal women.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Deroisy, Rita  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Lecart, M. P.
Sarlet, Nathalie ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Zegels, Brigitte ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Jupsin, Isabelle ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
de Longueville, M.
Franchimont, P.
Language :
English
Title :
A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss
Publication date :
May 1995
Journal title :
American Journal of Medicine
ISSN :
0002-9343
eISSN :
1555-7162
Publisher :
Excerpta Medica, United States - New York
Volume :
98
Issue :
5
Pages :
452-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 May 2010

Statistics


Number of views
66 (2 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
87
Scopus citations®
without self-citations
83
OpenCitations
 
61

Bibliography


Similar publications



Contact ORBi